Posts

Posted on

SeaSpine Announces Limited Commercial Launch of the WaveForm® L (Lateral) 3D-Printed Interbody System

CARLSBAD, Calif., June 08, 2021 (GLOBE NEWSWIRE) — SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the limited commercial launch of its 3D-printed WaveForm L (Lateral) Interbody System. 

WaveForm L is designed for the LLIF (lateral lumbar interbody fusion) procedure, and seamlessly integrates with the entire Regatta NanoMetalene® lateral interbody portfolio, including the recently launched Regatta Lateral Plate. WaveForm L delivers a fully porous interbody solution with a graft aperture designed to accommodate a large amount of SeaSpine’s best-in-class allograft demineralized bone matrix offerings OsteoStrand® and OsteoStrand® Plus.

“The WaveForm L implant from SeaSpine is one of the best new lateral cages currently on the market,” said Douglas Orndorff, Orthopedic surgeon, Durango, CO. “It incorporates the new 3D-printed technology with amazing gyroid geometry and optimum pore size for fusion. In addition, it has a large internal hollow core that allows surgeons to place a large amount of orthobiologics material into the core. This design can allow for a considerable amount of bony fusion throughout the entire cage.”

The WaveForm L interbody offers the next level of 3D-printed architectural innovation, balancing key geometric and manufacturing advancements without compromising clinical requirements. WaveForm L utilizes innovative WaveForm technology to deliver a highly porous and robust interbody solution. This design is intended to balance subsidence resistance, implant stiffness, and orthobiologics packability, while maintaining radiographic visualization during intraoperative and postoperative imaging.

“WaveForm L is our fourth entry into the 3D-printed interbody space, with the launch of a fifth implant for ALIF (anterior lumbar interbody fusion) procedures planned in the coming months,” said Dennis Cirino, Senior Vice President of Global Spinal Systems. “This new lateral system is the accumulation of decades of experience in lateral interbody design and orthobiologics that captures significant efficiencies from sharing the same instrumentation with our existing Regatta system.  With an extensive ability to pack orthobiologics in and around its innovative graft aperture, Waveform L also maximizes endplate contact without compromising strength or radiolucency.  We are excited to continue building out our WaveForm portfolio as we expand our procedural footprint.”

About SeaSpine

SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development, and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions, as well as a market leading surgical navigation system, to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic, and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in orthobiologic sciences, as well as spinal implants, software, and advanced optics product development, allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide through a committed network of increasingly exclusive distribution partners.

Forward-Looking Statements

SeaSpine cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that are based on the Company’s current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements relating to: the number of additional launches the Company plans this year in the 3D-printed interbody space; the design of WaveForm L and its ability to balance key geometric and manufacturing advancements without compromising clinical utility; and the ability of WaveForm technology to deliver a highly porous and robust interbody solution and appropriately balance subsidence resistance, implant stiffness, and orthobiologics packability, while maintaining radiographic visualization during intraoperative and postoperative imaging.. Among the factors that could cause or contribute to material differences between the Company’s actual results and the expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: unexpected expense and delay, including as a result of developing and supporting the launch of new products, such as Waveform L, the fact that newly launched products may require substantial additional development activities, which could introduce further expense and delay, or as a result of delay in timely obtaining regulatory clearances; the ability of newly launched products, such as WaveForm L, to perform as designed and intended and to meet the needs of surgeons and patients, including as a result of the lack of substantial clinical validation of products following limited commercial (or “alpha”) launch; and other risks and uncertainties more fully described in the Company’s news releases and periodic filings with the Securities and Exchange Commission. The Company’s public filings with the Securities and Exchange Commission are available at www.sec.gov.

You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. SeaSpine does not intend to revise or update any forward-looking statement set forth in this news release to reflect events or circumstances arising after the date hereof, except as may be required by law.

Investor Relations Contact

Leigh Salvo
(415) 937-5402
[email protected]



Posted on

HRB Brands Announces Acquisition of Personal Care Brands from Helen of Troy

Iconic Brands Such as Brut®, Pert®, Sure®, Ammens®, Seabreeze® and Infusium® Added to Company’s Growing Portfolio

NEW YORK, June 08, 2021 (GLOBE NEWSWIRE) — HRB Brands LLC (“HRB” or the “Company”), a portfolio company of Tengram Capital Partners (“Tengram”), announced today that it has acquired a portfolio of personal care brands from Helen of Troy Limited (Nasdaq: HELE). The acquired portfolio includes 12 iconic and well-known brands such as Brut, Pert, Sure, Ammens, Seabreeze and Infusium.  

“Today’s acquisition complements, leverages, and builds upon the Company’s robust portfolio of personal care brands. These well-known, iconic brands have strong consumer loyalty across distribution channels in North and South America,” commented Tengram’s Managing Partner and Chairman of HRB Brands, William Sweedler.

“This strategic acquisition also brings with it a significant opportunity for international expansion, as the brands are currently sold in a number of countries and will drive growth across our combined platform. In addition, our management team has already begun development of renewed marketing and product innovation across the acquired portfolio that we will be sharing with our retail partners this Spring,” Jim Daniels, Chief Executive Officer of HRB Brands.

In conjunction with this transformative transaction, the Company has decided to rename the business to signify the transformation and evolution which includes significantly more brands in new categories along with international reach. The new name will be HRB Brands which stands for Healthy Responsible Beauty Brands.

The transaction was financed by White Oak and Wells Fargo along with transaction advisory services from Hilco Global.

About HRB Brands LLC

HRB Brands is one of the largest independent branded personal care companies in North America. HRB Brands holds leading market positions in the hair care and skin cleansing categories with iconic brands including ZEST®, VO5®, COAST®, Rave® SGX NYC®, THICKER FULLER HAIR®, Zero Frizz®, AND LA LOOKS®. HRB Brands is a portfolio company of Tengram Capital Partners.

About Tengram Capital Partners

Tengram Capital Partners is a private equity firm exclusively focused on investments in leading middle-market consumer companies that own strong recognizable brands. The team has a diverse background of consumer investing and operating expertise that assists and guides company management to unlock the true potential of their brands. Tengram invests in both traditional “growth” and “restructuring/turnaround” situations in each of the public and private sectors. Other Tengram investments, current and past, include Tommie Copper, Tone it Up, Algenist, Lime Crime Beauty, Revive, DevaCurl, NEST Fragrances, Robert Graham, Hudson Jeans, and El Cap.  Additional information can be found at: http://www.tengramcapital.com.

About Helen of Troy

Helen of Troy Limited (NASDAQ: HELE) is a leading global consumer products company offering creative solutions for its customers through a strong portfolio of well-recognized and widely-trusted brands, including OXO, Hydro Flask, Vicks, Braun, Honeywell, PUR, Hot Tools and Drybar. We sometimes refer to these brands as our Leadership Brands. All trademarks herein belong to Helen of Troy Limited (or its subsidiaries) and/or are used under license from their respective licensors.



Media Contact

Katherine Nash Goehring
(512) 757-2566
[email protected]

Posted on

Pool Corporation To Present At The 44th Nasdaq Investor Conference

COVINGTON, La., June 08, 2021 (GLOBE NEWSWIRE) — Pool Corporation (Nasdaq:POOL) announced today that Mark W. Joslin, Senior Vice President and Chief Financial Officer, and Melanie Housey Hart, Vice President and Chief Accounting Officer, will be participating in investor meetings at the 44th Nasdaq Investor Conference on Tuesday, June 15, 2021, and Thursday, June 17, 2021. They will also be giving a virtual presentation on Thursday, June 17, 2021, at 8:30 AM Eastern Time.   Informational materials used during the conference will be posted on POOLCORP’s website on the morning of the conference.

Pool Corporation is the world’s largest wholesale distributor of swimming pool and related backyard products. POOLCORP operates approximately 400 sales centers in North America, Europe and Australia through which it distributes more than 200,000 national brand and private label products to roughly 120,000 wholesale customers. For more information about POOLCORP, please visit www.poolcorp.com.

CONTACT:

Curtis J. Scheel
Director of Investor Relations
985.801.5341
[email protected]



Posted on

Helius Medical Technologies, Inc. to Participate in Noble Capital Markets’ Virtual Road Show Series

NEWTOWN, Pa., June 08, 2021 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM), (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced its participation in Noble Capital Markets’ Virtual Road Show Series, presented by Channelchek, which is scheduled for Thursday, June 10, 2021.

The event will feature a corporate presentation followed by a Q&A session proctored by Noble Capital Markets’ Senior Research Analyst, Joe Gomes, featuring questions submitted by the audience.

The live webcast of the event is scheduled for June 10, 2021, at 1:00 p.m. Eastern. Register for the webcast here. A recording will be available on Channelchek and under the ‘Events’ section of the Helius Medical Technologies investor relations website at https://heliusmedical.com/index.php/investor-relations/events/upcoming-events.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNSTM). For more information, visit www.heliusmedical.com.

About the PoNS

TM

Device and PoNS Treatment

TM

The Portable Neuromodulation Stimulator (PoNSTM) is an innovative non-surgical device, inclusive of a controller and mouthpiece, which delivers electrical stimulation to the surface of the tongue to provide treatment of gait deficit. The PoNS device is indicated for use in the United States as a short term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (“MS”) and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only. It is authorized for sale in Canada as a class II, non-implantable, medical device intended as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS, and chronic balance deficit due to mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used in conjunction with physical therapy. The PoNSTM is an investigational medical device in the European Union (“EU”) and Australia (“AUS”). It is currently under premarket review by the AUS Therapeutic Goods Administration.

Investor Relations Contact:

Westwicke Partners on behalf of Helius Medical Technologies, Inc.
Jack Powell, Vice President
[email protected]



Posted on

LPL Financial to Present at the Virtual Morgan Stanley US Financials, Payments & CRE Conference

SAN DIEGO, June 08, 2021 (GLOBE NEWSWIRE) — LPL Financial LLC today announced that Chief Financial Officer Matt Audette will present at the virtual Morgan Stanley US Financials, Payments & CRE Conference on June 15.

The virtual presentation takes place at 2:00 p.m. ET. A live audio webcast of the presentation will be accessible at investor.lpl.com, with a replay available on the website beginning two hours after the presentation. The replay will remain available through July 6.


About LPL Financial


LPL Financial (Nasdaq: LPLA) was founded on the principle that the firm should work for the advisor, and not the other way around. Today, LPL is a leader* in the markets we serve, supporting more than 18,000 financial advisors, 800 institution-based investment programs and 450 independent RIA firms nationwide. We are steadfast in our commitment to the advisor-centered model and the belief that Americans deserve access to objective guidance from a financial advisor. At LPL, independence means that advisors have the freedom they deserve to choose the business model, services, and technology resources that allow them to run their perfect practice. And they have the freedom to manage their client relationships, because they know their clients best. Simply put, we take care of our advisors, so they can take care of their clients.

* Top RIA custodian (Cerulli Associates, 2019 U.S. RIA Marketplace Report)
No. 1 Independent Broker-Dealer in the U.S (Based on total revenues, Financial Planning magazine June 1996-2020)
No. 1 provider of third-party brokerage services to banks and credit unions (2020-2021 Kehrer Bielan Research & Consulting Annual TPM Report)

Securities and Advisory services offered through LPL Financial LLC, a registered investment advisor. Member FINRA/SIPC. We routinely disclose information that may be important to shareholders in the “Investor Relations” or “Press Releases” section of our website.

Investor Relations – Chris Koegel, (617) 897-4574
Media Relations – Lauren Hoyt-Williams, (980) 321-1232
investor.lpl.com/contactus.cfm



Posted on

SI-BONE to Present at the 2021 JMP Securities Life Sciences Conference

SANTA CLARA, Calif., June 08, 2021 (GLOBE NEWSWIRE) — SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming 2021 JMP Securities Life Sciences Conference. Management is scheduled to present on Thursday, June 17 at 2:30 p.m. Eastern Time / 11:30 a.m. Pacific Time.

Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: www.si-bone.com

About SI-BONE, Inc.
SI-BONE is a medical device company that pioneered minimally invasive surgery of the SI joint with the iFuse Implant System. Studies have shown that the SI joint can be a source of pain in 15% to 30% of chronic low back pain. The iFuse Implant™, commercially available since 2009, is the only SI joint fusion device supported by multiple prospective clinical studies, including two randomized controlled trials, showing improved pain, patient function and quality of life resulting from treatment. There are over 90 peer-reviewed publications demonstrating the safety, durable effectiveness, and biomechanical and economic benefits unique to the iFuse Implant (www.si-bone.com/results). This body of evidence has enabled multiple government and private insurance payors to establish coverage of the SI joint fusion procedure exclusively when performed with the iFuse Implant System.

The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. The iFuse Implant System is also intended for sacroiliac fusion to augment stabilization and immobilization of the sacroiliac joint in skeletally mature patients undergoing sacropelvic fixation as part of a lumbar or thoracolumbar fusion. In addition, the iFuse Implant System is intended for sacroiliac fusion in acute, non-acute, and non-traumatic fractures involving the sacroiliac joint. There are potential risks associated with the iFuse Implant System. It may not be appropriate for all patients and all patients may not benefit.

SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. ©2021 SI-BONE, Inc. All Rights Reserved. 06082021

Investor Contact:

Matt Bacso, CFA
[email protected]

Media Contact:

Joe Powers
[email protected]



Posted on

Stratus Properties Inc. Announces The Saint June, a Luxury Multi-Family Development in Barton Creek

Stratus Properties Inc. Announces The Saint June, a Luxury Multi-Family Development in Barton Creek

Project to Feature 182 Units with a Focus on Design Sustainability

Construction Financing in Place

AUSTIN, Texas–(BUSINESS WIRE)–
Stratus Properties Inc. (NASDAQ: STRS) (“Stratus” or the “Company”) today announced its plans and construction financing for The Saint June, a 182-unit luxury garden style multi-family development within the Amarra subdivision of the Barton Creek community. The Saint June will be built on approximately 36 acres and will be comprised of multiple buildings featuring one, two and three bedroom apartments for lease with exceptional amenities, including a resort style clubhouse, fitness center, pool and extensive green space.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210608006071/en/

Rendering of The Saint June (Photo: Business Wire)

Rendering of The Saint June (Photo: Business Wire)

William H. Armstrong III, Chairman and Chief Executive Officer, stated, “Our projects within the beautiful Barton Creek community focus on using sustainable design features, materials, and construction techniques to ensure we protect the natural setting. Similar to the recently announced Holden Hills project, The Saint June is designed to complement the hill country environment with a focus on sustainable luxury and will be another unique, high-quality property that is key to our successful strategy of developing and monetizing properties. This multi-family development project will offer apartments for lease, which will add value to our leasing segment operations in the long-term. The Saint June is the most recent addition to our growing pipeline of projects focused on sustainability, and is located minutes away from downtown Austin, offering tenants easy access to restaurants, shops and entertainment.”

The project will be owned by The Saint June, L.P., a Texas limited partnership. Project financing is in place and includes a construction loan to the limited partnership in the amount of approximately $30.3 million, guaranteed by Stratus, to finance approximately 55 percent of the estimated approximately $55 million project costs. The remaining estimated project costs will be funded by equity contributed to the limited partnership by Stratus and a new unrelated private equity investor. Stratus will receive 34.13 percent of the limited partnership’s equity in exchange for its contribution of the land, development costs to date and cash, and will manage the project.

Stratus expects to begin project construction before the end of the second quarter of 2021, subject to receiving a final county permit. First resident move-ins are planned for late 2022.

About Stratus Properties Inc.

Stratus is a diversified real estate company engaged primarily in the acquisition, entitlement, development, management, and sale of commercial, and multi-family and single-family residential real estate properties, real estate leasing, and the operation of hotel and entertainment businesses located in the Austin, Texas area and other select, fast-growing markets in Texas.

Forward-Looking Statements

This press release contains forward-looking statements in which Stratus discusses factors it believes may affect its future performance. Forward-looking statements are all statements other than statements of historical fact. The words “anticipates,” “may,” “can,” “could,” “plans,” “believes,” “potential,” “possible,” “estimates,” “expects,” “projects,” “targets,” “intends,” “likely,” “will,” “should,” “to be” and any similar expressions are intended to identify those assertions as forward-looking statements. Stratus cautions readers that forward-looking statements are not guarantees of future performance, and its actual results may differ materially from those anticipated, expected, projected or assumed in the forward- looking statements. Important factors that can cause Stratus’ actual results to differ materially from those anticipated in the forward-looking statements include, but are not limited to, Stratus’ ability to obtain final permits for and close the financing arrangements for the development of The Saint June and execute profitably on its development plan for The Saint June, Stratus’ ability to continue to effectively develop and execute its strategies, including its ability to develop, finance, construct and sell properties on its anticipated schedule and at prices its Board considers acceptable, Stratus’ ability to obtain various entitlements and permits, a decrease in the demand for real estate in select markets in Texas where Stratus operates, changes in economic, market and business conditions, the uncertain and ongoing impact of the COVID-19 pandemic, and other factors described in more detail under the heading “Risk Factors” in Stratus’ Annual Report on Form 10-K for the year ended December 31, 2020, filed with the U.S. Securities and Exchange Commission.

Investors are cautioned that many of the assumptions upon which Stratus’ forward-looking statements are based are likely to change after the forward-looking statements are made. Further, Stratus may make changes to its business plans that could affect its results. Stratus cautions investors that it does not intend to update its forward-looking statements more frequently than quarterly notwithstanding any changes in its assumptions, business plans, actual experience, or other changes, and Stratus undertakes no obligation to update any forward-looking statements.

A copy of this release is available on Stratus’ website, stratusproperties.com.

Financial and Media Contact:

William H. Armstrong III

(512) 478-5788

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Entertainment General Entertainment Residential Building & Real Estate Commercial Building & Real Estate Construction & Property REIT

MEDIA:

Photo
Photo
Rendering of The Saint June (Photo: Business Wire)
Posted on

Comtech Telecommunications Corp. Declares $0.10 Per Share Quarterly Cash Dividend

Comtech Telecommunications Corp. Declares $0.10 Per Share Quarterly Cash Dividend

MELVILLE, N.Y.–(BUSINESS WIRE)–
June 8, 2021– Comtech Telecommunications Corp. (NASDAQ: CMTL) announced today that its Board of Directors declared a quarterly cash dividend of $0.10 per share, payable on August 20, 2021, to shareholders of record at the close of business on July 21, 2021. The dividend is the Company’s forty-fourth consecutive quarterly dividend. Future dividends remain subject to compliance with financial covenants under the Company’s secured credit facility as well as Board approval.

Comtech Telecommunications Corp. is a leader in the global communications market headquartered in Melville, New York. With a passion for customer success, Comtech designs, produces and markets advanced secure wireless solutions to more than 1,000 customers in more than 100 countries.

Certain information in this press release contains statements that are forward-looking in nature and involve certain significant risks and uncertainties. Actual results could differ materially from such forward-looking information. The Company’s Securities and Exchange Commission filings identify many such risks and uncertainties. Any forward-looking information in this press release is qualified in its entirety by the risks and uncertainties described in such Securities and Exchange Commission filings.

PCMTL

Media Contacts:

Michael D. Porcelain, President and Chief Operating Officer

(631) 962-7000

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Semiconductor Aerospace Security Manufacturing Satellite Audio/Video Transport Other Technology Telecommunications Software Networks Internet Hardware Electronic Design Automation Logistics/Supply Chain Management Technology Other Communications Communications

MEDIA:

Logo
Logo
Posted on

Clarivate Announces Proposed Offerings of Ordinary Shares and Convertible Preferred Shares

PR Newswire

LONDON, June 8, 2021 /PRNewswire/ — Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, announced today that it has commenced concurrent proposed offerings of $750 million of ordinary shares, alongside which certain existing shareholders intend to offer $250 million of ordinary shares (the “Ordinary Share Offering”), and $1.25 billion of Series A Mandatory Convertible preferred shares (the “convertible preferred shares”) (the “Convertible Preferred Share Offering,” and together with the Ordinary Share Offering, the “Offerings”). Neither the completion of the Ordinary Share Offering nor the Convertible Preferred Share Offering is contingent upon completion of the other. The Offerings are both subject to market and other conditions, and there can be no assurance as to whether or when either Offering may be completed, if at all, or as to the actual size or terms of either Offering. Clarivate intends to use the net proceeds from the Offerings to finance a portion of the purchase price for its pending acquisition of ProQuest, announced on May 17, 2021. None of the Offerings is conditioned on consummation of the ProQuest acquisition. If the ProQuest acquisition is not consummated, Clarivate intends to use the net proceeds received by it from the Offerings for general corporate purposes.

Unless earlier converted or redeemed, each convertible preferred share will automatically convert into a variable number of Clarivate’s ordinary shares on or around June 1, 2024. The conversion terms, dividend rate and the other terms of the convertible preferred shares will be determined at the time of pricing of the Convertible Preferred Share Offering.

Citigroup is acting as sole global coordinator and joint book-running manager, and BofA Securities, RBC Capital Markets, Barclays, HSBC and J. P. Morgan are also acting as joint book-running managers for the Offerings. Evercore acted as a financial advisor to Clarivate.

Clarivate is conducting the Offerings pursuant to an effective shelf registration statement, including a base prospectus, under the Securities Act of 1933, as amended. Each of the Offerings is being made only by means of a separate prospectus supplement and the accompanying prospectus. Copies of the preliminary prospectus supplement and accompanying prospectus relating to either Offering may be obtained by contacting Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-800-831-9146 or by emailing [email protected]; BofA Securities, NC1-004-03-43; 200 North College Street, 3rd floor, Charlotte NC 28255-0001, Attn: Prospectus Department, Toll Free: 1 800 294 1322, Email: [email protected]; RBC Capital Markets, Attention: Equity Syndicate, 200 Vesey Street, 8th Floor, New York, NY 10281-8098, or by telephone at (877) 822-4089 or by email at [email protected]; Barclays, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by emailing [email protected] or calling 888-603-5847; HSBC at 1-866-811-8049 and J.P. Morgan at 212-834-4533. Before you invest in either Offering, you should read the applicable prospectus supplement relating to such Offering and accompanying prospectus, the registration statement and the other documents that Clarivate has filed with the Securities and Exchange Commission as incorporated by reference therein, for more complete information about Clarivate and the Offerings. Investors may obtain these documents for free by visiting the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Clarivate

Clarivate™ is a global leader in providing solutions to accelerate the lifecycle of innovation. Our bold mission is to help customers solve some of the world’s most complex problems by providing actionable information and insights that reduce the time from new ideas to life-changing inventions in the areas of science and intellectual property. We help customers discover, protect and commercialize their inventions using our trusted subscription and technology-based solutions coupled with deep domain expertise.

Forward-Looking Statements

This communication contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements, which express management’s current views concerning future business, events, trends, contingencies, financial performance, or financial condition, appear at various places in this communication and may use words like “aim,” “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “goal,” “intend,” “likely,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “see,” “seek,” “should,” “strategy,” “strive,” “target,” “will,” and “would” and similar expressions, and variations or negatives of these words. Examples of forward-looking statements include, among others, statements we make regarding: our pending acquisition of ProQuest; guidance outlook and predictions relating to expected operating results, such as revenue growth and earnings; strategic actions such as acquisitions, joint ventures, and dispositions, including the anticipated benefits therefrom, and our success in integrating acquired businesses; anticipated levels of capital expenditures in future periods; our ability to successfully realize cost savings initiatives and transition services expenses; our belief that we have sufficiently liquidity to fund our ongoing business operations; expectations of the effect on our financial condition of claims, litigation, environmental costs, the COVID-19 pandemic and governmental responses thereto, contingent liabilities, and governmental and regulatory investigations and proceedings; and our strategy for customer retention, growth, product development, market position, financial results, and reserves. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management’s current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Because forward-looking statements relate to the future, they are difficult to predict and many of which are outside of our control. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include those factors discussed under the caption “Risk Factors” in our most recent annual report on Form 10-K, as amended, along with our other filings with the U.S. Securities and Exchange Commission (“SEC”). However, those factors should not be considered to be a complete statement of all potential risks and uncertainties. Additional risks and uncertainties not known to us or that we currently deem immaterial may also impair our business operations. Forward-looking statements are based only on information currently available to our management and speak only as of the date of this communication. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. Please consult our public filings with the SEC.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/clarivate-announces-proposed-offerings-of-ordinary-shares-and-convertible-preferred-shares-301308352.html

SOURCE Clarivate Plc

Posted on

Karyopharm Announces Key Changes to Its Commercial Leadership Team

− Sohanya Cheng, Formerly of Amgen and Arrowhead Pharmaceuticals, Appointed as Head of Sales and Commercial Operations –

− Payman Darouian, Formerly of Novartis, Bristol Myers Squibb, and Sanofi, to Lead Marketing for XPOVIO® –

PR Newswire

NEWTON, Mass., June 8, 2021 /PRNewswire/ — Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced key management changes to its commercial organization, including the appointment of Sohanya Cheng, MBA, as Senior Vice President of Sales and Commercial Operations. Payman Darouian, PharmD, Senior Vice President of Marketing will lead all marketing activities for Karyopharm’s lead product, XPOVIO® (selinexor). In addition, John Demaree, Chief Commercial Officer, and Perry Monaco, Senior Vice President of Sales, will be leaving Karyopharm to pursue other opportunities.

“We are excited to welcome Sohanya to Karyopharm and to broaden Payman’s role within the organization as we continue to execute on the commercialization of XPOVIO® and expand its position in the treatment paradigm for multiple myeloma, diffuse large B-cell lymphoma, and potentially additional tumor types, if approved, in the future,” said Richard Paulson, MBA, President and Chief Executive Officer of Karyopharm. “I’d also like to take this opportunity to thank both John and Perry for their tremendous contributions to the initial commercial success of XPOVIO and sincerely wish them both success in their future endeavors.”

The Company does not currently plan to fill the position of Chief Commercial Officer and both Ms. Cheng and Dr. Darouian will report directly to Richard Paulson, President and Chief Executive Officer.

Ms. Cheng brings 17 years of biopharmaceutical commercialization and research experience to Karyopharm, predominately in the oncology space. Prior to joining Karyopharm, Ms. Cheng served as Vice President, Head of Marketing and Corporate Affairs at Arrowhead Pharmaceuticals and prior to this role, spent over 10 years within the commercial organization at Amgen. While at Amgen, Ms. Cheng held a variety of sales and marketing leadership roles supporting the commercialization of key oncology brands, including Kyprolis® for multiple myeloma and Blincyto® for acute lymphoblastic lymphoma, and served as Amgen’s Executive Director, Head of Marketing & Sales for their multiple myeloma business. Ms. Cheng holds an MBA from the MIT Sloan School of Management and a BSc and MA from the University of Cambridge, UK.

Dr. Darouian joined Karyopharm in January 2021 and is responsible for all marketing efforts for XPOVIO. Prior to joining Karyopharm, he spent more than 17 years in a variety of commercial leadership roles, predominately in the oncology space, including  at Novartis where Dr. Darouian served as the Executive Director and Global Brand Lead for Targeted Lung Cancer Therapies and also led commercial strategy for their Solid Tumor and Immuno-Oncology business. Prior to Novartis, Dr. Darouian helped lead worldwide commercialization of Opdivo® for the treatment of head and neck cancer at Bristol Myers Squibb. Finally, while at Sanofi, Dr. Darouian held numerous marketing leadership roles over an eight year period supporting key oncology brands, including Jevtana® and Eloxatin®. Dr. Darouian holds a PharmD from the Albany College of Pharmacy and a BS from the University of Massachusetts, Amherst.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of first-in-class drugs directed against nuclear export for the treatment of cancer and other diseases. Karyopharm’s Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s lead compound, XPOVIO® (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade® (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. NEXPOVIO® (selinexor) has also been granted conditional marketing authorization in combination with dexamethasone for adult patients with heavily pretreated multiple myeloma by the European Commission. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. For more information, please visit www.karyopharm.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Karyopharm’s expectations and plans relating to XPOVIO for the treatment of patients with relapsed or refractory multiple myeloma, diffuse large B-cell lymphoma and certain solid tumors. Such statements are subject to numerous important factors, risks and uncertainties, many of which are beyond Karyopharm’s control, that may cause actual events or results to differ materially from Karyopharm’s current expectations. For example, there can be no guarantee that Karyopharm will successfully commercialize XPOVIO. Further, there can be no guarantee that any positive developments in the development or commercialization of Karyopharm’s drug candidate portfolio will result in stock price appreciation. Management’s expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: the risk that the COVID-19 pandemic could disrupt Karyopharm’s business more severely than it currently anticipates, including by negatively impacting sales of XPOVIO, interrupting or delaying research and development efforts, impacting the ability to procure sufficient supply for the development and commercialization of selinexor or other product candidates, delaying ongoing or planned clinical trials, impeding the execution of business plans, planned regulatory milestones and timelines, or inconveniencing patients; the adoption of XPOVIO in the commercial marketplace, the timing and costs involved in commercializing XPOVIO or any of Karyopharm’s drug candidates that receive regulatory approval; the ability to retain regulatory approval of XPOVIO or any of Karyopharm’s drug candidates that receive regulatory approval; Karyopharm’s results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies, including with respect to the need for additional clinical studies; the ability of Karyopharm or its third party collaborators or successors in interest to fully perform their respective obligations under the applicable agreement and the potential future financial implications of such agreement; Karyopharm’s ability to obtain and maintain requisite regulatory approvals and to enroll patients in its clinical trials; unplanned cash requirements and expenditures; development or regulatory approval of drug candidates by Karyopharm’s competitors for products or product candidates in which Karyopharm is currently commercializing or developing; and Karyopharm’s ability to obtain, maintain and enforce patent and other intellectual property protection for any of its products or product candidates. These and other risks are described under the caption “Risk Factors” in Karyopharm’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, which was filed with the Securities and Exchange Commission (SEC) on May 4, 2021, and in other filings that Karyopharm may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by law, Karyopharm expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.

Cision View original content:http://www.prnewswire.com/news-releases/karyopharm-announces-key-changes-to-its-commercial-leadership-team-301308329.html

SOURCE Karyopharm Therapeutics Inc.